96 results on '"Cohen, Mauricio G."'
Search Results
2. Insulin provision therapy and mortality in older adults with diabetes mellitus and stable ischemic heart disease: Insights from BARI-2D trial
- Author
-
Damluji, Abdulla A., Cohen, Erin R., Moscucci, Mauro, Myerburg, Robert J., Cohen, Mauricio G., Brooks, Maria M., Rich, Michael W., and Forman, Daniel E.
- Published
- 2017
- Full Text
- View/download PDF
3. The association between in-hospital hemoglobin changes, cardiovascular events, and mortality in acute decompensated heart failure: Results from the ESCAPE trial
- Author
-
Damluji, Abdulla A., Macon, Conrad, Fox, Arieh, Garcia, Grettel, Al-Damluji, Mohammed S., Marzouka, George R., Myerburg, Robert J., Gilchrist, Ian C., Cohen, Mauricio G., and Moscucci, Mauro
- Published
- 2016
- Full Text
- View/download PDF
4. Clinical characteristics, process of care, and outcomes of Hispanic patients presenting with nonuST-segment elevation acute coronary syndromes: results from Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines (CRUSADE)
- Author
-
Cohen, Mauricio G., Roe, Matthew T., Mulgund, Jyotsna, Peterson, Eric D., Sonel, Ali F., Menon, Venu, Smith, Sidney C., Saucedo, Jorge F., Lytle, Barbara L., Pollack, Charles V., Jr., Garza, Luis, Gibler, W. Brian, and Ohman, E. Magnus
- Subjects
Hispanic Americans -- Health aspects ,Hispanic Americans -- Research ,Hispanic Americans -- Care and treatment ,Cardiac patients -- Health aspects ,Cardiac patients -- Care and treatment ,Cardiovascular diseases -- Care and treatment ,Cardiovascular diseases -- Patient outcomes ,Health - Published
- 2006
5. A simple prediction rule for significant renal artery stenosis in patients undergoing cardiac catheterization
- Author
-
Cohen, Mauricio G., Pascua, J. Andres, Garcia-Ben, Marta, Rojas-Matas, Carlos A., Gabay, Jose M., Berrocal, Daniel H., Tan, Walter A., Stouffer, George A., Montoya, Mario, Fernandez, Alejandro D., Halac, Marcelo E., and Grinfeld, Liliana R.
- Subjects
Renal artery obstruction -- Research ,Hypertension -- Causes of ,Cardiac catheterization -- Patient outcomes ,Health - Published
- 2005
6. Determinants of long-term dual antiplatelet therapy use in post myocardial infarction patients: Insights from the TIGRIS registry.
- Author
-
Russo, Juan J, Yan, Andrew T, Pocock, Stuart J, Brieger, David, Owen, Ruth, Sundell, Karolina Andersson, Bagai, Akshay, Granger, Christopher B, Cohen, Mauricio G, Yasuda, Satoshi, Nicolau, Jose C, Brandrup-Wognsen, Gunnar, Westermann, Dirk, Simon, Tabassome, and Goodman, Shaun G
- Abstract
• Dual-antiplatelet therapy (DAPT) ≥1 year post myocardial infarction reduces major adverse cardiovascular events but increases bleeding. • Appropriate patient selection for DAPT ≥1 year post myocardial infarction is important to avoid undue bleeding complications. • In contemporary practice, DAPT use ≥1 year post myocardial infarction is prevalent and associated with patient and index event characteristics. • There are marked geographical variations in DAPT use ≥1 year post myocardial infarction. • Further clinical initiatives are needed to optimize patient selection for DAPT ≥1 year post myocardial infarction. Patterns of dual antiplatelet therapy (DAPT) use beyond 1 year post-myocardial infarction (MI) have not been well studied. TIGRIS (NCT01866904) was a prospective, multi-center (369 centers in 24 countries), observational study of patients 1 to 3 years post-MI. We sought to identify the prevalence and determinants of DAPT use ≥1 year post-MI in patients enrolled in TIGRIS. We used multivariable logistic regression to identify determinants of DAPT use at 396 days post-MI (365 days plus a 31day overrun period to account for intended DAPT discontinuation at 1 year). Patients treated with an oral anticoagulant were excluded. Of 7708 patients (median age 67 years, women 25%, ST-elevation MI 50%), 39% and 16% were on DAPT at 396 days and 5 years post-MI, respectively. DAPT use at 396 days post-MI was more prevalent in patients <65 years of age, treated with percutaneous coronary intervention (versus coronary artery bypass grafting or medical therapy), and with multivessel disease or a history of angina. Additional clinical determinants of ischemic and/or bleeding events following MI (diabetes, second prior MI, hypertension, peripheral artery disease, heart failure, smoking, and renal insufficiency) were not independently associated with DAPT use at 396 days. There were geographic variations in the use of DAPT at 396 days (p <0.001), with the lowest use in Europe and the highest in Asia and Australia. In a contemporary patient cohort, DAPT use beyond 1 year post MI was prevalent and associated with patient and index event characteristics. There were marked geographical variations in DAPT use beyond 1 year post MI. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
7. Variation in patient management and outcomes for acute coronary syndromes in Latin America and North America: results from the Platelet IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial
- Author
-
Cohen, Mauricio G., Pacchiana, Cynthia M., Corbalan, Ramon, Perez, Jesus E. Isea, Ponte, Carlos I., Oropeza, Elsa Silva, Diaz, Rafael, Paolasso, Ernesto, Izasa, Daniel, Rodas, Marco A., Urrutia, Carlos E., Harrington, Robert A., Topol, Eric J., and Califf, Robert M.
- Subjects
Heart attack -- Care and treatment ,Discrimination in medical care -- Latin America ,Health - Published
- 2001
8. Regional Outcomes After Admission for High-Risk Non-ST-Segment Elevation Acute Coronary Syndromes
- Author
-
Menon, Venu, Rumsfeld, John S., Roe, Matthew T., Cohen, Mauricio G., Peterson, Eric D., Brindis, Ralph G., Chen, Anita Y., Pollack, Charles V., Smith, Sidney C., Gibler, W. Brian, and Ohman, E. Magnus
- Subjects
Coronary heart disease -- Care and treatment ,Therapeutics -- Health aspects ,Therapeutics -- Demographic aspects ,Homeopathy -- Materia medica and therapeutics ,Homeopathy -- Health aspects ,Homeopathy -- Demographic aspects ,Health ,Health care industry - Abstract
To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.amjmed.2006.01.018 Byline: Venu Menon (a), John S. Rumsfeld (b), Matthew T. Roe (c), Mauricio G. Cohen (d), Eric D. Peterson (c), Ralph G. Brindis (e), Anita Y. Chen (c), Charles V. Pollack (f), Sidney C. Smith (d), W. Brian Gibler (g), E. Magnus Ohman (c) Keywords: Acute coronary syndromes; Non-ST elevation myocardial infarction; Outcomes; Regional variation Abstract: An analysis of reginal variation across the United States in the treatment and outcomes of patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS) has not been previously performed. Author Affiliation: (a) Department of Cardiology, Cleveland Clinic Foundation, Cleveland, Ohio (b) Section of Cardiology, Denver VA Medical Center, Denver, Colo (c) Division of Cardiology and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (d) Division of Cardiology, University of North Carolina School of Medicine, Chapel Hill, NC (e) Oakland Kaiser Permanente Hospital, San Francisco, Calif (f) Department of Emergency Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pa (g) Department of Emergency Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio Article Note: (footnote) CRUSADE is a National Quality Improvement Initiative of the Duke Clinical Research Institute. CRUSADE is funded by Millennium Pharmaceuticals, Inc. (Cambridge, Mass) and Schering Corporation (Kenilworth, NJ). Bristol-Myers Squibb (Plainsboro, NJ)/Sanofi Pharmaceuticals (New York, NY) Partnership provides additional funding support.
- Published
- 2006
9. Opportunities for enhancing the care of older patients with ST-elevation myocardial infarction presenting for primary percutaneous coronary intervention: Rationale and design of the SAFE-STEMI for Seniors trial.
- Author
-
Rymer, Jennifer A., Mandawat, Aditya, Abbott, J. Dawn, Cohen, Mauricio G., Davies, Justin E., Gilchrist, Ian C., Jolly, Sanjit S., Popma, Jeffrey J., Al-Khalidi, Hussein R., Rao, Sunil V., Kong, David, and Krucoff, Mitchell
- Abstract
Advanced age is directly related to worse outcomes following ST-elevation myocardial infarction (STEMI) and higher complication rates from antithrombotic therapies and primary percutaneous coronary intervention (PCI). Often excluded from clinical trials, seniors presenting with STEMI remain an understudied population despite contributing to 140,000 hospital admissions annually. The SAFE-STEMI for Seniors study is a prospective, multicenter, unblinded, randomized clinical trial designed to examine the efficacy and safety of instantaneous wave-free ratio-guided complete revascularization in multivessel disease, while also investigating other components of STEMI care for patients ≥60 years including the efficacy and safety of zotarolimus-eluting stents for primary PCI and transradial PCI with the Glidesheath Slender and TR band. The SAFE-STEMI trial represents North America's first and only prospective randomized investigational device exemption study to use a Coordinated Registry Network infrastructure with collaborative partnering across industry manufacturers, promoting both efficiency and reduced cost of evidence development for regulatory decisions related to both diagnostic and therapeutic technologies in a single study design. The study has been powered to evaluate 2 independent co-primary end points in a population of older patients with STEMI: (1) third-generation drug-eluting stents for primary PCI and (2) instantaneous wave-free ratio-guided complete revascularization versus infarct-related artery-only revascularization. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
10. Transfemoral Approach for Coronary Angiography and Intervention: A Collaboration of International Cardiovascular Societies.
- Author
-
Damluji, Abdulla A., Nelson, Daniel W., Valgimigli, Marco, Windecker, Stephan, Byrne, Robert A., Cohen, Fernando, Patel, Tejas, Brilakis, Emmanouil S., Banerjee, Subhash, Mayol, Jorge, Cantor, Warren J., Alfonso, Carlos E., Rao, Sunil V., Moscucci, Mauro, and Cohen, Mauricio G.
- Abstract
Objectives The aim of this study was to examine the current practice and use of transfemoral approach (TFA) for coronary angiography and intervention. Background Wide variability exists in TFA techniques for coronary procedures. Methods The authors developed a survey instrument that was distributed via e-mail lists from professional societies to interventional cardiologists from 88 countries between March and December 2016. Results Of 987 operators, 18% were femoralists, 38% radialists, 42% both, and 2% neither. Access using femoral pulse palpation alone was preferred by 60% of operators, fluoroscopy guidance by 11%, and a combination of palpation, fluoroscopy, or ultrasound by 27%. Only 11% used micropuncture in >90% of their cases. Performing femoral angiography immediately after access was preferred by 23% and at the end of the procedure by 47%, and not done at all by 31% of operators. Hemostasis by manual compression was preferred by 50%, collagen plug vascular closure device by 31%, and suture-based vascular closure device by 11% of operators. Judkins left and right catheters were preferred for diagnostic angiography of the left (99%) and right (94%) coronary arteries. Extra backup curves (XB or EBU) were most commonly preferred for percutaneous coronary intervention of the left anterior descending (80%) and left circumflex (80%), whereas the Judkins right catheter was preferred for percutaneous coronary intervention of the right coronary artery (86%). Conclusions There is significant variability in preferences for femoral access technique. Even though recommended best practices advocate for fluoroscopic and ultrasound guidance, most operators use palpation alone. Femoral angiography is also not consistently used despite guideline recommendations. The lack of adoption of imaging guidance for vascular access deserves further investigation. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
11. Percutaneous Coronary Revascularization in Patients Undergoing TAVR: A Different Entity or More of the Same?
- Author
-
Escárcega, Ricardo O., Cohen, Mauricio G., and Mathur, Moses
- Published
- 2022
- Full Text
- View/download PDF
12. Key Concepts Surrounding Cardiogenic Shock.
- Author
-
Krittanawong, Chayakrit, Rivera, Mario Rodriguez, Shaikh, Preet, Kumar, Anirudh, May, Adam, Mahtta, Dhruv, Jentzer, Jacob, Civitello, Andrew, Katz, Jason, Naidu, Srihari S., Cohen, Mauricio G., and Menon, Venu
- Abstract
Cardiogenic shock (CS) is the final common pathway of impaired cardiovascular performance that results in ineffective forward cardiac output producing clinical and biochemical signs of organ hypoperfusion. CS represents the most common cause of shock in the cardiac intensive care unit (CICU) and accounts for a substantial proportion of CICU patient deaths. Despite significant advances in revascularization techniques, pharmacologic therapeutics and mechanical support devices, CS remains associated with a high mortality rate. Indeed, the prevalence of CS within the CICU appears to be increasing. CS can be differentiated as phenotypes reflecting different metabolic, inflammatory, and hemodynamic profiles, depending also on anatomic substrate and congestion profile. Future prospective studies and clinical trials may further characterize these phenotypes and apply targeted intervention for each phenotype and SCAI SHOCK stage rather than a one-size-fits-all approach. Overall, there are 8 key concepts of CS; 1) the mortality associated with CS; 2) Shock attributed to AMI may be declining in both incidence and associated mortality; 3) providers should think about hemodynamic, metabolic, inflammation and cardiac function in totality to assess CS; 4) CS is a dynamic process; 5) no randomized trials evaluating use of the PAC in patients with CS; 6) most data supporting neosynephrine as first line agent in CS; 7) most registries suggest that almost half of CS patients do not have any mechanical support, and the vast majority of the remainder utilize the IABP; and 8) patients with AMI CS should receive emergent PCI of the culprit vessel. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
13. Percutaneous left ventricular assist device for high-risk percutaneous coronary interventions: Real-world versus clinical trial experience.
- Author
-
Cohen, Mauricio G., Matthews, Ray, Maini, Brij, Dixon, Simon, Vetrovec, George, Wohns, David, Palacios, Igor, Popma, Jeffrey, Ohman, E. Magnus, Schreiber, Theodore, O’Neill, William W., and O'Neill, William W
- Abstract
Background: High-risk percutaneous coronary intervention (PCI) supported by percutaneous left ventricular assist devices offers a treatment option for patients with severe symptoms, complex and extensive coronary artery disease, and multiple comorbidities. The extrapolation from clinical trial to real-world practice has inherent uncertainties. We compared the characteristics, procedures, and outcomes of high-risk PCI supported by a microaxial pump (Impella 2.5) in a multicenter registry versus the randomized PROTECT II trial (NCT00562016).Methods: The USpella registry is an observational multicenter voluntary registry of Impella technology. A total of 637 patients treated between June 2007 and September 2013 were included. Of them, 339 patients would have met enrollment criteria for the PROTECT II trial. These were compared with 216 patients treated in the Impella arm of PROTECT II.Results: Compared to the clinical trial, registry patients were older (70 ± 11.5 vs 67.5 ± 11.0 years); more likely to have chronic kidney disease (30% vs 22.7%), prior myocardial infarction (69.3% vs 56.5%), or prior bypass surgery (39.4% vs. 30.2%); and had similar prevalence of diabetes, peripheral vascular disease, and prior stroke. Registry patients had more extensive coronary artery disease (2.2 vs 1.8 diseased vessels) and had a similar Society of Thoracic Surgeons predicted risk of mortality. At hospital discharge, registry patients experienced a similar reduction in New York Heart Association class III to IV symptoms compared to trial patients. Registry patients had a trend toward lower in-hospital mortality (2.7% vs 4.6, P = .27).Conclusions: USpella provides a real-world and contemporary estimation of the type of procedures and outcomes of high-risk patients undergoing PCI supported by Impella 2.5. Despite the higher risk of registry patients, clinical outcomes appeared to be favorable and consistent compared with the randomized trial. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
14. Diagnostic and Guide Catheter Selection and Manipulation for Radial Approach.
- Author
-
Alfonso, Carlos E. and Cohen, Mauricio G.
- Published
- 2015
- Full Text
- View/download PDF
15. The association between body mass index and coronary artery disease severity: A comparison of black and white patients.
- Author
-
Stalls, Caleb M., Triplette, Matthew A., Viera, Anthony J., Pathman, Donald E., Cohen, Mauricio G., and Rossi, Joseph S.
- Abstract
Introduction: Despite known associations between obesity and cardiovascular disease, the relationship between obesity as reflected by body mass index (BMI) and angiographic coronary artery disease (CAD) is not fully understood. Moreover, this relationship has not been adequately defined in black patients, a group demonstrated to have lower rates of angiographic CAD despite higher rates of CAD risk factors, cardiovascular events, and CAD-related mortality. Methods: Using an angiography database from an academic hospital, we studied patients undergoing first-time, nonemergent coronary angiography. From this cohort, we selected those without previous CAD diagnosis and with complete anthropomorphic measures and outcome data. Using models that controlled for patient demographics and CAD risk factors, we compared rates of angiographic CAD for blacks and whites by BMI. Results: Black patients had higher rates of CAD risk factors, including obesity and morbid obesity. Nevertheless, black patients were less likely to have a significant stenosis than white patients. Morbid obesity was associated with significantly less CAD in both race groups. Controlling for black-white differences in BMI and the prevalence of morbid obesity did not change the odds ratio for CAD among black patients. Conclusions: Racial differences in BMI and prevalence of morbid obesity do not contribute to black-white differences in CAD detected during elective angiography. The paradoxical association of morbid obesity with a lower burden of atherosclerosis may be attributed in part to the limitations of noninvasive screening in the morbidly obese and subsequent referral of patients without disease for angiography. [Copyright &y& Elsevier]
- Published
- 2014
- Full Text
- View/download PDF
16. Predictors of J-point elevation in a cross sectional US cohort
- Author
-
Badheka, Apurva O., Patel, Nileshkumar J., Singh, Vikas, Deshmukh, Abhishek, Shah, Neeraj, Grover, Peeyush, Rathod, Ankit, Chothani, Ankit, Mehta, Kathan, Savani, Ghanshyam, Myerburg, Robert J., Mitrani, Raul D., and Cohen, Mauricio G.
- Published
- 2013
- Full Text
- View/download PDF
17. Meta-analysis of PCI vs. CABG for left main disease revisited.
- Author
-
Kuno, Toshiki, Ueyama, Hiroki, Rao, Sunil V, Cohen, Mauricio G, Tamis-Holland, Jacqueline E, Thompson, Craig, Takagi, Hisato, and Bangalore, Sripal
- Published
- 2020
- Full Text
- View/download PDF
18. The Kinetics of Integrilin Limited by Obesity: A multicenter randomized pharmacokinetic and pharmacodynamic clinical trial.
- Author
-
Vavalle, John P., Stevens, Susanna R., Hassinger, Nancy, Cohen, Mauricio G., Arnold, Anita, Kandzari, David E., Aguirre, Frank V., Gretler, Daniel D., and Alexander, John H.
- Abstract
Background: KILO tested 2 novel weight-based eptifibatide dosing strategies compared with standard dosing in obese patients undergoing elective percutaneous coronary intervention (PCI). Eptifibatide dosing is weight adjusted for patients up to 121 kg. Patients above this weight receive the same maximal dose, although it is unknown if this provides adequate eptifibatide concentration or platelet inhibition. Methods: Sixty-seven patients weighing ≥125 kg undergoing elective PCI were randomized to 1 of 3 eptifibatide dosing regimens: standard dosing using a weight of 121 kg, actual body weight (ABW)–based dosing with no upper limit, or ideal body weight (IBW)–based dosing. Boluses of 180 μg/kg were given 10 minutes apart, followed by a 2.0 μg/kg per minute infusion. Plasma eptifibatide concentrations were drawn at 12 to 18 hours after initiating the infusion. Platelet aggregation was assessed at baseline and 10 minutes after the second bolus. Results: Sixty-seven patients were randomized to standard (n = 22), ABW (n = 23), or IBW (n = 22) dosing. The median (25th, 75th) steady-state plasma eptifibatide concentrations were 1,740 ng/mL (1,350, 2,350), 1,780 ng/mL (1,510, 2,350), and 1,055 ng/mL (738, 1,405), respectively (P < .001). Ten-minute median (25th, 75th) platelet aggregation units were 7 (0, 21), 2 (0, 8), and 14 (8, 20), respectively (P = .001). Conclusions: Actual body weight eptifibatide dosing leads to higher plasma concentrations and greater platelet inhibition than standard or IBW dosing in obese patients undergoing PCI. Current recommendations for eptifibatide dosing may be inadequate in patients >121 kg. Further study is warranted to define the optimal dosing of eptifibatide and other medications in obese patients. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
19. Insights into the inhibition of platelet activation by omega-3 polyunsaturated fatty acids: Beyond aspirin and clopidogrel
- Author
-
Cohen, Mauricio G., Rossi, Joseph S., Garbarino, Jennifer, Bowling, Regina, Motsinger-Reif, Alison A., Schuler, Carl, Dupont, Allison G., and Gabriel, Don
- Subjects
- *
BLOOD platelets , *FATTY acids , *ASPIRIN , *CLOPIDOGREL , *ELECTROPHORESIS , *LIGHT scattering , *ARACHIDONIC acid , *EICOSAPENTAENOIC acid - Abstract
Abstract: Objectives: We sought to examine the effects of escalating doses of omega-3 polyunsaturated fatty acid (PUFA) supplements on platelet function using light transmission aggregometry (LTA) and electrophoretic quasi-elastic light scattering technology (EQELS). Background: PUFA may inhibit platelet function through fatty acid substitution in the platelet membrane by changing the surface charge density and causing decreased production of thromboxane A2. EQELS can measure platelet surface charge density and determine whether the platelet is in resting or activated state. Methods: A total of 30volunteers were divided in 3 groups of 10 as follows: Group A, no antiplatelet agent; Group B, daily aspirin only, and Group C, daily aspirin and clopidogrel. All patients received escalating doses of omega-3PUFA from 1 to 8g daily over 24weeks. Platelet function was measured by template bleeding time, LTA, and EQELS at baseline and at 6, 12, 18 and 24weeks. Results: Mean bleeding time increased in a dose-dependent manner with escalating omega-3 PUFA doses. LTA confirmed expected antiplatelet effects of aspirin and clopidogrel, but did not detect any additional antiplatelet effects of omega-3 PUFA. EQELS showed a significant increase in the negative resting platelet charge compared to baseline and an attenuated response to arachidonic acid mediated platelet activation. No bleeding events were observed. Conclusions: In this pilot study we were able to successfully measure platelet surface charge variation as a measure of omega-3 PUFA effect on platelets. Our results suggest that omega-3 PUFA increase the total platelet surface charge and, therefore, attenuate platelet activation, even among patients taking aspirin or aspirin plus clopidogrel. Further studies are needed to determine the clinical significance of these measured effects and EQELS results. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
20. The Transradial Approach to Percutaneous Coronary Intervention: Historical Perspective, Current Concepts, and Future Directions
- Author
-
Rao, Sunil V., Cohen, Mauricio G., Kandzari, David E., Bertrand, Olivier F., and Gilchrist, Ian C.
- Subjects
- *
ANGIOPLASTY , *HEART disease related mortality , *CLINICAL trials , *COMPLICATIONS of cardiac surgery , *CORONARY disease , *LENGTH of stay in hospitals ,HEART hemorrhage - Abstract
Periprocedural bleeding complications after percutaneous coronary intervention (PCI) are associated with increased short- and long-term morbidity and mortality. Although clinical trials have primarily assessed pharmacological strategies for reducing bleeding risk, there is a mounting body of evidence suggesting that adoption of a transradial rather than a transfemoral approach to PCI may permit greater reductions in bleeding risk than have been achieved with pharmacological strategies alone. However, despite a long history of use, a lack of widespread uptake by physicians coupled with the technological limitations of available devices has in the past confined transradial PCI to the status of a niche procedure, and many operators lack experience in this technique. In this review, we examine the history of the transradial approach to PCI and discuss some of the circumstances that have hitherto limited its appeal. We then review the current state of the peer-reviewed literature supporting its use and summarize the unresolved issues affecting broader application of this technique, including lack of operator familiarity and an insufficient evidence base for guiding practice. Finally, we describe potential directions for future investigation in the transradial realm. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
21. Therapeutic Goals in Patients With Refractory Chronic Angina.
- Author
-
Cohen, Mauricio G., Pascual, Mario, Sciric, Benjamin M., and Magnus Ohman, E.
- Subjects
ANGINA pectoris treatment ,QUALITY of life ,ATHEROSCLEROSIS treatment ,CORONARY disease ,STATINS (Cardiovascular agents) ,MYOCARDIAL revascularization ,HEMODYNAMICS - Abstract
Copyright of Revista Española de Cardiología (18855857) is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2010
- Full Text
- View/download PDF
22. Should the Benefit of Transradial Access Still Be Questioned?
- Author
-
Cohen, Mauricio G. and Ohman, E. Magnus
- Published
- 2016
- Full Text
- View/download PDF
23. Latino patients' preferences for medication information and pharmacy services.
- Author
-
Sleath, Betsy, Blalock, Susan J., Bender, Deborah E., Murray, Michael, Cerna, Ana, and Cohen, Mauricio G.
- Subjects
DRUGS ,PHARMACEUTICAL services ,HISPANIC Americans ,DRUGSTORES ,SPANISH language - Abstract
Objectives: To examine (1) Latino patient's language preferences for receiving verbal and written medication information in community pharmacies. (2) the types of problems and concerns Latino patients report about using their medications, and (3) the factors that Latino patients believe are important when choosing a community pharmacy. Methods: Individuals were eligible to participate if they were 18 years of age or older, if they self-identified as being Latino, and if they or their children were currently taking prescription medications. All 93 participating individuals were interviewed in Spanish. Results: The majority of patients did not always receive their prescription labels or written medication information in Spanish. Approximately 52% of the respondents preferred to receive verbal information in Spanish without an interpreter, and 21.5% preferred to receive it in Spanish with an interpreter. Most respondents (70%) preferred written information in Spanish, and 21.5% preferred written information in both Spanish and English. The most commonly reported problems were difficulty paying for medications, difficulty reading the English on the prescription labels, and adverse effects. Participants valued pharmacies with friendly and respectful employees. Conclusion: Study participants reported many problems or concerns in using their medications, and the majority preferred receiving written and verbal information about their medication in Spanish. Pharmacies need to find better ways of providing services to the rapidly growing Latino population. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
24. The paradoxical use of cardiac catheterization in patients with non–ST-elevation acute coronary syndromes: Lessons from the Can Rapid Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC /AHA ...
- Author
-
Cohen, Mauricio G., Filby, Steven J., Roe, Matthew T., Chen, Anita Y., Menon, Venu, Stouffer, George A., Gibler, W. Brian, Smith, Sidney C., Pollack, Charles V., Peterson, Eric D., and Ohman, E. Magnus
- Abstract
Background: The long-term benefits of coronary revascularization are proportional to the severity of underlying coronary artery disease (CAD). We sought to identify patients with a greater probability of severe CAD to target those who could receive the greatest benefit from revascularization. Methods: We used multivariable logistic generalized estimating equations modeling to identify clinical factors associated with severe CAD in 83,490 patients, without prior bypass surgery, who underwent coronary angiography after presenting with non–ST-segment elevation acute coronary syndromes enrolled in CRUSADE. We then compared actual patterns of cardiac catheterization use relative to patients'' probability of severe CAD in those who underwent catheterization and those who did not. Results: Independent factors associated with severe CAD included older age, male sex, diabetes, no prior percutaneous coronary intervention, signs or history of heart failure, prior myocardial infarction, ST-segment depression, and family history of CAD. Cardiac catheterization rates were inversely related to the probability of severe CAD as estimated by the model. Conclusions: There is a misalignment in the use of cardiac catheterization in patients with non–ST-segment elevation acute coronary syndromes relative to their predicted probability of severe CAD. The use of catheterization appears to target patients who would derive less benefit from revascularization. Further quality improvement efforts should promote appropriate use of cardiac catheterization procedures among patients with the greatest potential benefit. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
25. Percutaneous coronary intervention or coronary artery bypass graft surgery for left main coronary artery disease: A meta-analysis of randomized trials.
- Author
-
Kuno, Toshiki, Ueyama, Hiroki, Rao, Sunil V., Cohen, Mauricio G., Tamis-Holland, Jacqueline E., Thompson, Craig, Takagi, Hisato, and Bangalore, Sripal
- Abstract
We aimed to investigate long-term (≥5 years) outcomes of percutaneous coronary intervention (PCI) versus coronary artery bypass grafting (CABG) for left main coronary artery disease (LMCAD) using a meta-analysis from updated published randomized trials. Our data showed that the risk of all-cause death as well as cardiovascular death, myocardial infarction, and stroke was similar between PCI and CABG, whereas PCI had significantly higher rates of repeat revascularization compared to CABG. Decisions for PCI versus CABG for LMCAD should be based on weighing the upfront morbidity and mortality risk of CABG with late risk of repeat revascularization with PCI and taking into consideration patient preference. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
26. Clinical characteristics, process of care, and outcomes of Hispanic patients presenting with non–ST-segment elevation acute coronary syndromes: Results from Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes ...
- Author
-
Cohen, Mauricio G., Roe, Matthew T., Mulgund, Jyotsna, Peterson, Eric D., Sonel, Ali F., Menon, Venu, Smith, Sidney C., Saucedo, Jorge F., Lytle, Barbara L., Pollack, Charles V., Garza, Luis, Gibler, W. Brian, and Ohman, E. Magnus
- Subjects
HEART diseases ,MORTALITY ,CATHETERIZATION - Abstract
Background: Data regarding the management of non–ST-segment elevation acute coronary syndromes (NSTE ACS) in Hispanic patients, the largest and fastest-growing minority in the United States, are scarce. Methods: We sought to describe the clinical characteristics, process of care, and outcomes of Hispanics presenting with NSTE ACS at US hospitals. We compared baseline characteristics, resource use, and inhospital mortality among 3936 Hispanics and 90280 non-Hispanic whites with NSTE ACS from the CRUSADE Quality Improvement Initiative. Results: The regional distribution of Hispanics in CRUSADE paralleled that in the US Census. Hispanics were younger (65 vs 70 years, P < .0001) and had less hyperlipidemia (45.4% vs 49.0%, P < .0001) but were more likely to be hypertensive (72.2% vs 67.9%, P < .0001) and diabetic (46.5% vs 30.9%, P < .0001). Hispanics were also more likely to be uninsured (12.5% vs 5.1%, P < .001). During hospitalization, Hispanics were more often managed conservatively, undergoing stress tests more frequently (13.0% vs 10.1%, P < .0001), with less use of cardiac catheterization within 48 hours (48.7% vs 55.5%, P < .0001) or percutaneous coronary intervention (39.6% vs 46.4%, P < .0001) at any time. Hispanics received similar discharge treatments but were less frequently referred for cardiac rehabilitation (38.5% vs 49.2%, P < .0001). Adjusted inhospital mortality was similar in both groups (odds ratio 0.87, 95% CI 0.72-1.05). Conclusions: Although hispanics have a different risk factor profile and are treated less aggressively during hospitalization when they present with NSTE ACS, these treatment differences do not appear to affect inhospital outcomes. Further research is warranted to explore the long-term consequences of these findings. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
27. Transcutaneous ultrasound-facilitated coronary thrombolysis during acute myocardial infarction
- Author
-
Cohen, Mauricio G., Tuero, Enrique, Bluguermann, Jorge, Kevorkian, Rubén, Berrocal, Daniel H., Carlevaro, Oscar, Picabea, Eduardo, Hudson, Michael P., Siegel, Robert J., Douthat, Lori, Greenbaum, Adam B., Echt, Debra, Weaver, W. Douglas, and Grinfeld, Liliana R.
- Subjects
- *
THROMBOLYTIC therapy , *MYOCARDIAL infarction - Abstract
In preclinical experiments, the combination of transcutaneous, low-frequency ultrasound and thrombolytic therapy has shown improved patency rates over thrombolytics alone. A total of 25 patients with myocardial infarction were treated with a thrombolytic agent and adjunctive transcutaneous ultrasound. No unanticipated major adverse events were observed. [Copyright &y& Elsevier]
- Published
- 2003
- Full Text
- View/download PDF
28. Outcomes following interventions in small coronary arteries with the use of hand-crimped...
- Author
-
Cohen, Mauricio G. and Kong, David F.
- Subjects
- *
CORONARY artery surgery , *VASCULAR surgery , *SURGICAL stents - Abstract
Examines procedural, in-hospital and long-term outcomes of patients undergoing small coronary artery stenting with Palmaz-Schatz stents hand-crimped on a balloon catheter. Suggestion that stents designed for vessels greater than three millimeters can be deployed in small vessels with a low in-hospital event rate; High lesion revascularization in small vessels.
- Published
- 2000
- Full Text
- View/download PDF
29. Future Perspectives of Left Main Revascularization Trials.
- Author
-
Kuno, Toshiki, Ueyama, Hiroki, Rao, Sunil V., Cohen, Mauricio G., Tamis-Holland, Jacqueline E., Thompson, Craig, Takagi, Hisato, and Bangalore, Sripal
- Published
- 2021
- Full Text
- View/download PDF
30. The incidence of acute kidney injury after cardiac catheterization or PCI: A comparison of radial vs. femoral approach.
- Author
-
Damluji, Abdulla, Cohen, Mauricio G., Smairat, Ramez, Steckbeck, Robert, Moscucci, Mauro, and Gilchrist, Ian C.
- Published
- 2014
- Full Text
- View/download PDF
31. Intracoronary Thrombus: A Sticky Problem ⁎ [⁎] Editorials published in JACC: Cardiovascular Interventions reflect the views of the authors and do not necessarily represent the views of JACC: Cardiovascular Interventions or the ...
- Author
-
Cohen, Mauricio G.
- Published
- 2010
- Full Text
- View/download PDF
32. Staying ahead of the curve.
- Author
-
Rao, Sunil V. and Cohen, Mauricio G.
- Published
- 2014
- Full Text
- View/download PDF
33. TCT-20 Use of a Percutaneous Left Ventricular Assist Device for High Risk Percutaneous Coronary Interventions. Clinical Trial versus Real World Experience.
- Author
-
Cohen, Mauricio G., Matthews, Ray V., Maini, Brij, Dixon, Simon, Vetrovec, George W., Wohns, David H., Palacios, Igor F., Popma, Jeffrey, Ohman, E. Magnus, Schreiber, Theodore, and O'Neill, William W.
- Subjects
- *
PERCUTANEOUS coronary intervention , *HEART assist devices , *CLINICAL trials , *CARDIAC research , *MEDICAL research , *MEDICAL publishing - Published
- 2015
- Full Text
- View/download PDF
34. New-onset versus prior history of atrial fibrillation: Outcomes from the AFFIRM trial.
- Author
-
Damluji, Abdulla A., Al-Damluji, Mohammed S., Marzouka, George R., Coffey, James O., Viles-Gonzalez, Juan F., Cohen, Mauricio G., Moscucci, Mauro, Myerburg, Robert J., and Mitrani, Raul D.
- Abstract
Background There are limited data on prognosis and outcomes of patients with new-onset atrial fibrillation (AF) compared with those with a prior history of AF. Methods and results We conducted a comparison of these 2 groups in the AFFIRM trial. New-onset AF was the qualifying arrhythmia in 1,391 patients (34%). Compared with patients with prior history of AF, patients with new-onset AF were more likely to have a history of heart failure. There was no mortality difference between rate control (RaC) and rhythm control (RhC) among patients with new-onset AF (17% vs 20%, P = .152). In the univariate model, new-onset AF was associated with increased risk of mortality compared with history of prior AF (RaC unadjusted hazard ratio [HR] 1.36 [ P = .010], RhC unadjusted HR 1.39 [ P = .003]). However, after multivariate adjustments, new-onset AF did not carry an increased risk of mortality (RaC adjusted HR 1.14 [ P = .370], RhC adjusted HR 1.16 [ P = .248]). Subjects with new-onset AF randomized to the RhC arm were more likely to remain in normal sinus rhythm at follow-up (adjusted HR 0.79, P = .012) compared with patients with prior history of AF. Conclusions In a multivariable analysis adjusting for confounders, new-onset AF was not associated with increased mortality compared with prior history of AF regardless of the treatment strategy. Patients with new-onset AF treated with the rhythm control strategy were more likely to remain in normal sinus rhythm on follow-up. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
35. Left Ventricular Assist Improves 90 Day Outcomes With Unprotected Left Main Coronary Intervention: Analysis From The Protect II Trial.
- Author
-
Heldman, Alan W., Cohen, Mauricio G., Dixon, Simon, Moses, Jeffrey W., Palacios, Igor F., Pershad, Ashish, and O'Neill, William W.
- Published
- 2013
- Full Text
- View/download PDF
36. A randomized, partially blinded, multicenter, active-controlled, dose-ranging study assessing the safety, efficacy, and pharmacodynamics of the REG1 anticoagulation system in patients with acute coronary syndromes: Design and rationale of the RADAR ...
- Author
-
Povsic, Thomas J., Cohen, Mauricio G., Mehran, Roxana, Buller, Christopher E., Bode, Christoph, Cornel, Jan H., Kasprzak, Jarosław D., Montalescot, Gilles, Joseph, Diane, Wargin, William A., Rusconi, Christopher P., Zelenkofske, Steven L., Becker, Richard C., and Alexander, John H.
- Abstract
Anticoagulants are the cornerstone of current acute coronary syndrome (ACS) therapy; however, anticoagulation regimens that aggressively reduce ischemic events are almost uniformly associated with more bleeding. REG1, an anticoagulation system, consists of RB006 (pegnivacogin), an RNA oligonucleotide factor IXa inhibitor, and RB007 (anivamersen), its complementary controlling agent. Phase I and IIa studies defined predictable relationships between doses of RB006, RB007, and degree of antifactor IX activity. The efficacy and safety of REG1 for the treatment of patients with ACS managed invasively and the safety of reversing RB006 with RB007 after cardiac catheterization are unknown. Randomized, partially-blinded, multicenter, active-controlled, dose-ranging study assessing the safety, efficacy, and pharmacodynamics of the REG1 anticoagulation system compared to unfractionated heparin or low molecular heparin in subjects with acute coronary syndrome (RADAR) is designed to assess both the efficacy of the anticoagulant RB006 and the safety of a range of levels of RB006 reversal with RB007. The objectives of RADAR are (1) to determine the safety of a range of levels of RB006 reversal with RB007 after catheterization, (2) to confirm whether a dose of 1 mg/kg RB006 results in near-complete inhibition of factor IXa in patients with ACS, and (3) to assess the efficacy of RB006 as an anticoagulant in patients with ACS undergoing percutaneous coronary intervention. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
37. FACTOR IXA INHIBITION WITH REG1 PROVIDES RAPID ONSET, STABLE AND ACTIVELY CONTROLLED ANTICOAGULATION DURING PCI
- Author
-
Cohen, Mauricio G., Purdy, Drew A., Rossi, Joseph S., Grinfeld, Liliana R., Myles, Shelley K., Aberle, Laura H., Greenbaum, Adam B., Fry, Edward, Chan, Mark Y., Zelenkofske, Steven, Alexander, John H., Harrington, Robert A., Rusconi, Christopher P., and Becker, Richard C.
- Published
- 2010
- Full Text
- View/download PDF
38. 2022 ACC/AHA Key Data Elements and Definitions for Chest Pain and Acute Myocardial Infarction: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Data Standards.
- Author
-
Anderson, H.V. ("Skip"), Masri, Sofia Carolina, Abdallah, Mouin S., Chang, Anna Marie, Cohen, Mauricio G., Elgendy, Islam Y., Gulati, Martha, LaPoint, Kathleen, Madan, Nidhi, Moussa, Issam D., Ramirez, Jorge, Simon, April W., Singh, Vikas, Waldo, Stephen W., Williams, Marlene S., and Writing Committee Members
- Subjects
- *
MYOCARDIAL infarction , *CHEST pain , *ST elevation myocardial infarction , *CARDIOLOGY , *HEART - Published
- 2022
- Full Text
- View/download PDF
39. New-Onset Atrial Fibrillation After Aortic Valve Replacement: Comparison of Transfemoral, Transapical, Transaortic, and Surgical Approaches.
- Author
-
Tanawuttiwat, Tanyanan, O'Neill, Brian P., Cohen, Mauricio G., Chinthakanan, Orawee, Heldman, Alan W., Martinez, Claudia A., Alfonso, Carlos E., Mitrani, Raul D., Macon, Conrad J., Carrillo, Roger G., Williams, Donald B., O'Neill, William W., and Myerburg, Robert J.
- Subjects
- *
ATRIAL fibrillation , *SURGERY , *AORTIC stenosis , *RETROSPECTIVE studies , *COHORT analysis , *PATIENTS ,AORTIC valve surgery - Abstract
Objectives: This study sought to determine the incidence of new-onset atrial fibrillation (AF) associated with different methods of isolated aortic valve replacement (AVR)—transfemoral (TF), transapical (TA), and transaortic (TAo) catheter-based valve replacement and conventional surgical approaches. Background: The relative incidences of AF associated with the various access routes for AVR have not been well characterized. Methods: In this single-center, retrospective cohort study, we evaluated a total of 231 consecutive patients who underwent AVR for degenerative aortic stenosis (AS) between March 2010 and September 2012. Patients with a history of paroxysmal, persistent, or chronic AF, with bicuspid aortic valves, and patients who died within 48 h after AVR were excluded. A total of 123 patients (53% of total group) qualified for inclusion. Data on documented episodes of new-onset AF, along with all clinical, echocardiographic, procedural, and 30-day follow-up data, were collated. Results: AF occurred in 52 patients (42.3%). AF incidence varied according to the procedural method. AF occurred in 60% of patients who underwent surgical AVR (SAVR), in 53% after TA-TAVR, in 33% after TAo-TAVR cases, and 14% after TF-TAVR. The episodes occurred at a median time interval of 53 (25th to 75th percentile, 41 to 87) h after completion of the procedure. Procedures without pericardiotomy had an 82% risk reduction of AF compared with those with pericardiotomy (adjusted odds ratio: 0.18; 95% confidence interval: 0.05 to 0.59). Conclusions: AF was a common complication of AVR with a cumulative incidence of >40% in elderly patients with degenerative AS who underwent either SAVR or TAVR. AF was most common with SAVR and least common with TF-TAVR. Procedures without pericardiotomy were associated with a lower incidence of AF. [Copyright &y& Elsevier]
- Published
- 2014
- Full Text
- View/download PDF
40. Antithrombotic Treatment in Transcatheter Aortic Valve Implantation: Insights for Cerebrovascular and Bleeding Events.
- Author
-
Rodés-Cabau, Josep, Dauerman, Harold L., Cohen, Mauricio G., Mehran, Roxana, Small, Eric M., Smyth, Susan S., Costa, Marco A., Mega, Jessica L., O'Donoghue, Michelle L., Ohman, E. Magnus, and Becker, Richard C.
- Subjects
- *
ANTICOAGULANTS , *CARDIAC catheterization , *ARTIFICIAL implants , *BRAIN disease treatment , *CEREBROVASCULAR disease , *HEMORRHAGE treatment ,AORTIC valve surgery - Abstract
Transcatheter aortic valve implantation (TAVI) has emerged as a therapeutic alternative for patients with symptomatic aortic stenosis at high or prohibitive surgical risk. However, patients undergoing TAVI are also at high risk for both bleeding and stroke complications, and specific mechanical aspects of the procedure itself can increase the risk of these complications. The mechanisms of periprocedural bleeding complications seem to relate mainly to vascular/access site complications (related to the use of large catheters in a very old and frail elderly population), whereas the pathophysiology of cerebrovascular events remains largely unknown. Further, although mechanical complications, especially the interaction between the valve prosthesis and the native aortic valve, may play a major role in events that occur during TAVI, post-procedural events might also be related to a prothrombotic environment or state generated by the implanted valve, the occurrence of atrial arrhythmias, and associated comorbidities. Antithrombotic therapy in the setting of TAVI has been empirically determined, and unfractionated heparin during the procedure followed by dual antiplatelet therapy with aspirin (indefinitely) and clopidogrel (1 to 6 months) is the most commonly recommended treatment. However, bleeding and cerebrovascular events are common; these may be modifiable with optimization of periprocedural and post-procedural pharmacology. Further, as the field of antiplatelet and anticoagulant therapy evolves, potential drug combinations will multiply, introducing variability in treatment. Randomized trials are the best path forward to determine the balance between the efficacy and risks of antithrombotic treatment in this high risk-population. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
41. Procedural Effectiveness With a Focused Force Scoring Angioplasty Catheter: Procedural and Clinical Outcomes From the Scoreflex NC Trial.
- Author
-
Kandzari, David, Hearne, Steven, Kumar, Gautam, Sachdeva, Rajesh, Adams, George, Blossom, Benjamin, Dahle, Thom, Sanghvi, Kintur, Cohen, Mauricio G., Imperi, Gregory, Riley, Robert, and Almonacid, Alexandra Popma
- Subjects
- *
TRANSLUMINAL angioplasty , *ANGIOPLASTY , *PERCUTANEOUS coronary intervention , *CATHETERS , *TREATMENT effectiveness , *MYOCARDIAL infarction , *RESEARCH , *RESEARCH methodology , *MEDICAL care , *EVALUATION research , *CARDIOVASCULAR system , *CORONARY angiography , *COMPARATIVE studies , *MYOCARDIAL revascularization , *LONGITUDINAL method - Abstract
Background: The Scoreflex NC scoring angioplasty catheter is designed with a short rapid-exchange tip distal to a non-compliant, high-pressure balloon and an integral wire outside of the balloon, such that the guidewire and the integral wire act as scoring elements during balloon inflation. The external scoring elements enable a focal stress pattern facilitating expansion of resistant lesions at lower pressures using a focused force angioplasty effect.Methods: Patients undergoing elective percutaneous coronary intervention (PCI) were enrolled in a prospective, single-arm study conducted at 12 centers in the United States. The primary endpoint was device procedural success, defined as the composite of successful device delivery to the target lesion with balloon inflation and deflation; absence of vessel perforation, flow-limiting dissection or reduction in TIMI flow from baseline; and achievement of final TIMI 3 flow.Results: Among 200 patients (234 lesions), lesion complexities included: bifurcation disease (37.6%), moderate/severe calcification (36.6%), and total occlusions (5.0%). Successful delivery to the target lesion, inflation and removal of the balloon catheter was achieved in 95.5% of patients (191/200). Procedural success was achieved in 93.5% (187/200) of patients, and final TIMI 3 flow was observed in 99.0% of cases (198/200). No unanticipated device-related events occurred. In-hospital major adverse events were reported in 4.5% of patients (9/200), related to periprocedural myocardial infarction (8/200, 4.0%) and target lesion revascularization (1/200, 0.5%).Conclusions: Among patients undergoing elective PCI and with varied lesion complexity, these results support the safety and effectiveness of a dilation strategy using the Scoreflex NC scoring catheter. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
42. Antiplatelet therapies and the role of antiplatelet resistance in acute coronary syndrome
- Author
-
Dupont, Allison G., Gabriel, Don A., and Cohen, Mauricio G.
- Subjects
- *
ANTICOAGULANTS , *DRUG resistance , *CORONARY disease , *HEALTH outcome assessment , *PATIENTS , *CARDIOVASCULAR diseases ,DEVELOPED countries - Abstract
Abstract: Acute coronary syndrome is the number one killer in the industrialized world and, as such, continues to be one of the most well-studied disease states in all of medicine. Advancements in antiplatelet therapies for use in patients undergoing percutaneous coronary intervention have improved outcomes dramatically. However, a proportion of patients on long-term antiplatelet therapy continue to have cardiovascular events. Resistance to antiplatelet drugs may explain some of these events and this topic has become one of major interest and rapid evolution. This review describes the pathogenesis of acute coronary syndromes, outlines the evidence behind the use of the available antiplatelet agents, and examines the current data surrounding antiplatelet resistance. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
43. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
- Author
-
Lawton, Jennifer S., Tamis-Holland, Jacqueline E., Bangalore, Sripal, Bates, Eric R., Beckie, Theresa M., Bischoff, James M., Bittl, John A., Cohen, Mauricio G., DiMaio, J. Michael, Don, Creighton W., Fremes, Stephen E., Gaudino, Mario F., Goldberger, Zachary D., Grant, Michael C., Jaswal, Jang B., Kurlansky, Paul A., Mehran, Roxana, Metkus, Thomas S., Nnacheta, Lorraine C., and Rao, Sunil V.
- Subjects
- *
CORONARY artery bypass , *CORONARY arteries , *CARDIOPULMONARY bypass , *CORONARY artery disease , *PERCUTANEOUS coronary intervention , *HEART , *CARDIOLOGY , *SYSTEMATIC reviews , *MYOCARDIAL revascularization - Abstract
Aim: The guideline for coronary artery revascularization replaces the 2011 coronary artery bypass graft surgery and the 2011 and 2015 percutaneous coronary intervention guidelines, providing a patient-centric approach to guide clinicians in the treatment of patients with significant coronary artery disease undergoing coronary revascularization as well as the supporting documentation to encourage their use.Methods: A comprehensive literature search was conducted from May 2019 to September 2019, encompassing studies, reviews, and other evidence conducted on human subjects that were published in English from PubMed, EMBASE, the Cochrane Collaboration, CINHL Complete, and other relevant databases. Additional relevant studies, published through May 2021, were also considered.Structure: Coronary artery disease remains a leading cause of morbidity and mortality globally. Coronary revascularization is an important therapeutic option when managing patients with coronary artery disease. The 2021 coronary artery revascularization guideline provides recommendations based on contemporary evidence for the treatment of these patients. The recommendations present an evidence-based approach to managing patients with coronary artery disease who are being considered for coronary revascularization, with the intent to improve quality of care and align with patients' interests. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
44. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
- Author
-
Lawton, Jennifer S., Tamis-Holland, Jacqueline E., Bangalore, Sripal, Bates, Eric R., Beckie, Theresa M., Bischoff, James M., Bittl, John A., Cohen, Mauricio G., DiMaio, J. Michael, Don, Creighton W., Fremes, Stephen E., Gaudino, Mario F., Goldberger, Zachary D., Grant, Michael C., Jaswal, Jang B., Kurlansky, Paul A., Mehran, Roxana, Metkus, Thomas S., Nnacheta, Lorraine C., and Rao, Sunil V.
- Subjects
- *
CORONARY artery bypass , *CORONARY arteries , *PERCUTANEOUS coronary intervention , *TRANSLUMINAL angioplasty , *CORONARY artery disease , *READING strategies , *DIABETES , *RISK assessment , *MYOCARDIAL revascularization , *HEALTH care teams , *ALGORITHMS - Abstract
Aim: The executive summary of the American College of Cardiology/American Heart Association/Society for Cardiovascular Angiography and Interventions coronary artery revascularization guideline provides the top 10 items readers should know about the guideline. In the full guideline, the recommendations replace the 2011 coronary artery bypass graft surgery guideline and the 2011 and 2015 percutaneous coronary intervention guidelines. This summary offers a patient-centric approach to guide clinicians in the treatment of patients with significant coronary artery disease undergoing coronary revascularization, as well as the supporting documentation to encourage their use.Methods: A comprehensive literature search was conducted from May 2019 to September 2019, encompassing studies, reviews, and other evidence conducted on human subjects that were published in English from PubMed, EMBASE, the Cochrane Collaboration, CINHL Complete, and other relevant databases. Additional relevant studies, published through May 2021, were also considered.Structure: Recommendations from the earlier percutaneous coronary intervention and coronary artery bypass graft surgery guidelines have been updated with new evidence to guide clinicians in caring for patients undergoing coronary revascularization. This summary includes recommendations, tables, and figures from the full guideline that relate to the top 10 take-home messages. The reader is referred to the full guideline for graphical flow charts, supportive text, and tables with additional details about the rationale for and implementation of each recommendation, and the evidence tables detailing the data considered in the development of this guideline. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
45. Two-year outcomes among stable high-risk patients following acute MI. Insights from a global registry in 25 countries.
- Author
-
Brieger, David, Pocock, Stuart J., Blankenberg, Stefan, Chen, Ji Yan, Cohen, Mauricio G., Granger, Christopher B., Grieve, Richard, Nicolau, Jose C., Simon, Tabassome, Westermann, Dirk, Yasuda, Satoshi, Gregson, John, Rennie, Kirsten L., Hedman, Katarina, Sundell, Karolina Andersson, and Goodman, Shaun G.
- Subjects
- *
ANGINA pectoris , *CORONARY disease , *OLDER patients , *CHRONIC kidney failure , *CARDIOVASCULAR diseases - Abstract
Evidence is lacking on long-term outcomes in unselected patients surviving the first year following myocardial infarction (MI). The TIGRIS (long-Term rIsk, clinical manaGement and healthcare Resource utilization of stable coronary artery dISease in post-myocardial infarction patients) prospective registry enrolled 9176 eligible patients aged ≥50 years, 1–3 years post-MI, from 25 countries. All had ≥1 risk factor: age ≥ 65 years, diabetes mellitus, second prior MI, multivessel coronary artery disease, chronic kidney disease (CKD). Primary outcome was a composite of MI, unstable angina with urgent revascularization, stroke, or all-cause death at 2-year follow-up. Bleeding requiring hospitalization was also recorded. 9027 patients (98.4%) provided follow-up data: the primary outcome occurred in 621 (7.0%), all-cause mortality in 295 (3.3%), and bleeding in 109 (1.2%) patients. Events accrued linearly over time. In multivariable analyses, qualifying risk factors were associated with increased risk of primary outcome (incidence rate ratio [RR] per 100 patient-years [95% confidence interval]): CKD 2.06 (1.66, 2.55), second prior MI 1.71 (1.38, 2.10), diabetes mellitus 1.63 (1.39, 1.92), age ≥ 65 years 1.53 (1.28, 1.83), and multivessel disease 1.24 (1.05, 1.48). Risk of bleeding events was greater in older patients (vs <65 years) 65–74 years 2.68 (1.53, 4.70), ≥75 years 4.62 (2.57, 8.28), and those with CKD 1.99 (1.18, 3.35). In stable patients recruited 1–3 years post-MI, recurrent cardiovascular and bleeding events accrued linearly over 2 years. Factors independently predictive of ischemic and bleeding events were identified, providing a context for deciding on treatment options. • TIGRIS enrolled stable patients 1–3 years post-MI, all with ≥1 risk factor. • Among 9027 patients, the primary outcome occurred in 7.0%. • All qualifying risk factors were associated with increased risk of primary outcome. • Older age and chronic kidney disease were associated with increased bleeding risk. • These findings provide a context for treatment decisions. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
46. 2020 AHA/ACC Key Data Elements and Definitions for Coronary Revascularization: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Clinical Data Standards for Coronary Revascularization)
- Author
-
Dehmer, Gregory J., Badhwar, Vinay, Bermudez, Edmund A., Cleveland, Joseph C., Cohen, Mauricio G., D'Agostino, Richard S., Ferguson, T. Bruce, Hendel, Robert C., Isler, Maria Lizza, Jacobs, Jeffrey P., Jneid, Hani, Katz, Alan S., Maddox, Thomas M., and Shahian, David M.
- Subjects
- *
CARDIOGENIC shock , *AORTIC dissection , *TASK forces , *DEFINITIONS , *MEDICAL sciences , *CORONARY disease , *CARDIOLOGY - Published
- 2020
- Full Text
- View/download PDF
47. Culprit Vessel Only Versus Multivessel Percutaneous Coronary Intervention in Acute Myocardial Infarction with Cardiogenic Shock: A Systematic Review and Meta-Analysis.
- Author
-
Khalid, Muhammad Faisal, Khan, Abdul Ahad, Khattak, Furqan, Ayub, Muhammad Talha, Bagai, Jayant, Mukherjee, Debabrata, Helton, Thomas, Cohen, Mauricio G., Banerjee, Subhash, and Paul, Timir K.
- Subjects
- *
PERCUTANEOUS coronary intervention , *CARDIOGENIC shock , *MYOCARDIAL infarction , *META-analysis , *CORONARY disease - Abstract
Background: Previous studies comparing outcomes between culprit vessel only percutaneous coronary intervention (CV-PCI) versus multivessel percutaneous coronary intervention (MV-PCI) in patients with cardiogenic shock in the setting of acute myocardial infarction have shown conflicting results. This meta-analysis investigates the optimal approach for management of these patients considering recently published data.Methods: Electronic databases including MEDLINE, ClinicalTrials.gov and the Cochrane Library were searched for all clinical studies published until May 1, 2018, which compared outcomes in patients presenting with acute myocardial infarction and cardiogenic shock. Studies comparing CV-PCI versus MV-PCI in patients with multivessel coronary artery disease were screened for inclusion in final analysis. The primary end point was in-hospital/30 day mortality. Secondary endpoints included long term (>6 months) mortality, renal failure requiring renal replacement therapy, stroke, bleeding, and recurrent myocardial infarction. Odds ratio (OR) with 95% of confidence interval (CI) were computed and p values <0.05 were considered significant.Results: Patient who underwent CV-PCI had significantly lower short-term mortality (in-hospital or 30-day mortality) (OR: 0.73, CI: 0.61-0.87, p = 0.0005), and lower odds of severe renal failure requiring renal replacement therapy (OR: 0.76, CI: 0.59-0.98, p = 0.03). There was no statistically significant difference in long-term mortality, stroke, bleeding, and recurrent myocardial infarction between two groups.Conclusion: This meta-analysis showed lower short-term mortality and decreased odds of renal failure requiring renal replacement therapy with CV-PCI compared to MV-PCI. However, subgroup analysis including studies exclusively assessing STEMI patients revealed no statistically significant difference in outcomes. Further randomized trials are needed to confirm these findings and evaluate long term results. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
48. Percutaneous Coronary Intervention in Older Patients With ST-Segment Elevation Myocardial Infarction and Cardiogenic Shock.
- Author
-
Damluji, Abdulla A, Bandeen-Roche, Karen, Berkower, Carol, Boyd, Cynthia M, Al-Damluji, Mohammed S, Cohen, Mauricio G, Forman, Daniel E, Chaudhary, Rahul, Gerstenblith, Gary, Walston, Jeremy D, Resar, Jon R, and Moscucci, Mauro
- Abstract
Background: Older adults ≥75 years of age carry an increased risk of mortality after ST-segment elevation myocardial infarction (STEMI) complicated by cardiogenic shock.Objectives: The purpose of this study was to examine the use of percutaneous coronary intervention (PCI) in older adults with STEMI and shock and its influence on in-hospital mortality.Methods: We used a large publicly available all-payer inpatient health care database sponsored by the Agency for Healthcare Research and Quality between 1999 and 2013. The primary outcome was in-hospital mortality. The influence of PCI on in-hospital mortality was assessed by quintiles of propensity score (PS).Results: Of the 317,728 encounters with STEMI and shock in the United States, 111,901 (35%) were adults age ≥75 years. Of these, 53% were women and 83% were Caucasians. The median number of chronic conditions was 8 (interquartile range: 6 to 10). The diagnosis of STEMI and cardiogenic shock in older patients decreased significantly over time (proportion of older adults with STEMI and shock: 1999: 42% vs. 2013: 29%). Concomitantly, the rate of PCI utilization in older adults increased (1999: 27% vs. 2013: 56%, p < 0.001), with declining in-hospital mortality rates (1999: 64% vs. 2013: 46%; p < 0.001). Utilizing PS matching methods, PCI was associated with a lower risk of in-hospital mortality across quintiles of propensity score (Mantel-Haenszel odds ratio: 0.48; 95% confidence interval [CI]: 0.45 to 0.51). This reduction in hospital mortality risk was seen across the 4 different U.S. census bureau regions (adjusted odds ratio: Northeast: 0.41; 95% CI: 0.36 to 0.47; Midwest: 0.49; 95% CI: 0.42 to 0.57; South: 0.51; 95% CI: 0.46 to 0.56; West: 0.46; 95% CI: 0.41 to 0.53).Conclusions: This large and contemporary analysis shows that utilization of PCI in older adults with STEMI and cardiogenic shock is increasing and paralleled by a substantial reduction in mortality. Although clinical judgment is critical, older adults should not be excluded from early revascularization based on age in the absence of absolute contraindications. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
49. Safety and efficacy of radial versus femoral access for rotational Atherectomy: A systematic review and meta-analysis.
- Author
-
Khan, Abdul Ahad, Panchal, Hemang B., Zaidi, Syed Imran M., Papireddy, Muralidhar R., Mukherjee, Debabrata, Cohen, Mauricio G., Banerjee, Subhash, Rao, Sunil V., Pancholy, Samir, and Paul, Timir K.
- Subjects
- *
ENDARTERECTOMY , *META-analysis , *PERCUTANEOUS coronary intervention , *LENGTH of stay in hospitals , *HOSPITAL mortality , *RADIATION exposure , *INTRAVENOUS catheterization , *INFORMATION storage & retrieval systems , *MEDICAL databases , *OPERATIVE surgery , *SYSTEMATIC reviews , *CORONARY disease , *FEMORAL artery , *RISK assessment , *TREATMENT effectiveness , *RADIAL artery , *CALCINOSIS , *MYOCARDIAL revascularization , *MEDLINE - Abstract
Introduction: Over the recent years, there has been increased interest in the use of transradial (TR) access for percutaneous coronary intervention (PCI), including rotational atherectomy (RA). However, a large proportion of operators seem to be reluctant to use TR access for complex PCI including rotational atherectomy for heavily calcified coronary lesions.Methods: We searched MEDLINE, ClinicalTrials.gov and the Cochrane Library for studies comparing radial versus femoral access in patients undergoing RA. Studies were included if they reported at least one of the following outcomes in each group separately: major adverse cardiac events (MACE), major bleeding, stent thrombosis, myocardial infarction (MI), hospital length of stay, radiation exposure, procedure time, procedure success and all-cause mortality. Odds ratio (OR) or mean difference (MD) with 95% confidence interval (CI) were calculated and a p-value of <0.05 was considered as a level of significance.Results: This meta-analysis included 5 retrospective studies with 3315 patients undergoing RA via radial access and 5838 patients via femoral access. Radial access was associated with lower major access site bleeding (OR: 0.45, 95% CI: 0.31-0.67, p < 0.001), and radiation exposure (MD: -16.1, 95%CI: -25.4--6.7 Gy cm2, p = 0.0007). There were no significant differences observed in all-cause in-hospital mortality (OR: 0.92, 95% CI: 0.69-1.23, p = 0.58); MACE (OR: 0.80, CI: 0.63, 1.02, p = 0.08), stent thrombosis (OR: 0.28, 95%CI: 0.06-1.33 p = 0.11); and MI (OR: 0.43, 95%CI: 0.15-1.24, p = 0.12). There were no significant differences in hospital stay, procedure time or procedure success between the two groups (p > 0.05).Conclusion: This meta-analysis of 9153 patients from observational studies demonstrates similar all-cause mortality, MACE, procedural success and procedural time during RA performed using TR access and TF access. However, TR access was associated with decreased access site bleeding and radiation exposure. Given the observational nature of these findings, a randomized controlled trial is warranted for further evidence. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
50. Influence of operator experience and PCI volume on transfemoral access techniques: A collaboration of international cardiovascular societies.
- Author
-
Nelson, Daniel W., Banerjee, Subhash, Mayol, Jorge, Cantor, Warren J., Rao, Sunil V., Moscucci, Mauro, Damluji, Abdulla A., Patel, Nish, Alfonso, Carlos E., Cohen, Mauricio G., Valgimigli, Marco, Windecker, Stephan, Byrne, Robert, Nolan, James, Patel, Tejas, and Brilakis, Emmanouil
- Subjects
- *
FEMORAL artery , *PERCUTANEOUS coronary intervention , *PALPITATION , *CARDIOVASCULAR diseases , *CORONARY angiography , *DATA analysis , *SURGERY - Abstract
Introduction: Transfemoral access (TFA) is widely used for coronary angiography and percutaneous coronary intervention (PCI). The influence of operator age, gender, experience, and procedural volume on performance of femoral arterial access has not been studied.Methods: A survey instrument was developed and distributed via e-mail from professional societies to interventional cardiologists worldwide from March to December 2016.Results: A total of 988 physicians from 88 countries responded to the survey. TFA is the preferred approach for patients with cardiogenic shock, left main or bifurcation PCI, and procedures with mechanical circulatory support. Older (<50years: 56.4%; ≥50years: 66.8%, p<0.0039) and high PCI volume operators (<100 PCI: 57.3%; 100-299 PCI: 58.7%; ≥300 PCI: 64.3%, p<0.134) preferred palpation only without imaging (fluoroscopy or ultrasound (US)) for TFA. Most respondents preferred not to use micropuncture needle to puncture the femoral artery. Older (≥50years: 64.4%; <50years: 71.5%, p<0.04) and high PCI volume operators (≥300 PCI: 64.1%; 100-299 PCI: 72.6%; <100 PCI: 67.9%, p<0.072) tended not to perform femoral angiography (FA). Of those performing FA, the majority opted to do it at the end of the procedure.Conclusion: Despite best practice guideline recommendations, older and high PCI volume interventional cardiologists prefer not to use imaging for femoral access or perform femoral angiography during TF procedures. These data highlight opportunities to further reduce TFA complications. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.